ViaCyte

ViaCyte

ViaCyte

Viacyte is a regenerative medicine company dedicated to improving the way diabetes patients are treated.
Type
B2c
Founded
1999
Raised
$192.5M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$27,000,000
Venture capital (Series D) - 2020
RA Capital Management Sanderling Ventures TPG Capital +1
$80,000,000
Venture capital (Series D) - 2018
RA Capital Management TPG Bain Capital Life Sciences
Team Size
50+
Employees
$27,000,000 Venture capital (Series D)
FinSMEs

ViaCyte Closes Approximately $27M in Series D Financing

$80,000,000 Venture capital (Series D)
PE HUB

ViaCyte nabs $80 mln Series D

MedCity News , Xconomy

CRISPR Therapeutics, ViaCyte partner on diabetes therapies

Xconomy

ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product

Robotics Health Science
$3,900,000 Grant
The San Diego Union-Tribune

CIRM grants ViaCyte $3.9 million for diabetes stem cell therapy

Xconomy

ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics

Science Health